- •
Clonal myeloid diseases include the myeloproliferative neoplasms: chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), chronic eosinophilic leukemia (CEL), and systemic mastocytosis (SM); and acute myeloid leukemia (AML).
- •
Clonal myeloid diseases have in common the mutational activation of cellular kinases that play an important role in driving aberrant cell proliferation.
- •
Therapeutic targeting of activated cellular kinases has had
Targeting Aberrant Signaling in Myeloid Malignancies: Promise Versus Reality
Section snippets
Key points
What makes a good drug-target pairing?
TKIs have been successful in the treatment of CML for clearly identifiable reasons. First and foremost, the ABL kinase domain is highly amenable to drug targeting. Second, the pathways that are activated by BCR-ABL play an essential role in the pathophysiology of CML. Third, inhibition of ABL does not result in unacceptable toxicity. Several decades of work identifying, validating, and targeting oncogenic enzymes has taught us that, for a drug-target pairing to be truly successful, all 3 of
Drugging the undruggable
Not all cancer-associated activating mutations in signaling proteins are amenable to molecular targeting. A classic example is the RAS family of small GTPases. RAS GTPases are among the most frequently mutated genes in cancer, and more than 10% of AML cases harbor activating RAS mutations.23 Despite years of research, efforts to directly inhibit RAS have, to date, been unsuccessful.24 One challenge to targeting RAS is structural. Unlike the ATP-binding domains of tyrosine kinases, which are
Oncogene addiction versus disease acceleration
In 2014, 3 groups reported that a significant proportion of older individuals with normal blood counts harbor somatic mutations in their hematopoietic stem cell compartment in genes associated with hematologic malignancies.31, 32, 33 This subclinical clonal hematopoiesis, termed clonal hematopoiesis of indeterminate potential (CHIP), is associated with an increased risk of developing hematologic malignancies. Prior studies on the mutational hierarchy of AML found that mutations in several
On-target toxicity as a therapeutic liability
Dysregulated JAK2 activation is the most common molecular feature of BCR-ABL–negative MPN. More than 90% of PV cases and approximately 50% of ET and PMF cases harbor JAK2V617F mutations,11 and most JAK2V617F-negative ET and PMF cases harbor mutations in either Calreticulin (CALR) or the thrombopoietin receptor (MPL),40, 41, 42 both of which act to aberrantly activate JAK2 signaling. JAK2 activation appears to play a central role in the pathogenesis of BCR-ABL–negative MPN, and the observation
Where do we go from here?
The example of TKIs for the treatment of CML provides an important proof-of-concept that therapeutic targeting of kinases can have profound clinical benefits, but numerous efforts to target other oncogenic kinases have been less successful. A pessimist might view these setbacks as evidence that BCR-ABL is a unique oncogenic kinase that is not representative of the role of kinase signaling in cancer. But as we have discussed here, there is mounting experimental and clinical evidence to suggest
Summary
Although the extraordinary success of targeting BCR-ABL in CML has not, until now, been recapitulated in other diseases, much has been learned from these failures that will inform future efforts to target kinase signaling. Advances in our understanding of how kinase signaling promotes cellular transformation, and the advent of novel treatment strategies, are reasons for renewed optimism that more effective targeting of signaling pathways is not only possible, but is likely to significantly
References (58)
- et al.
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Blood
(2016) - et al.
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
Cancer Cell
(2005) - et al.
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia
Blood
(2004) - et al.
Single cell analysis exposes intratumor heterogeneity and suggests that FLT3-ITD is a late event in leukemogenesis
Exp Hematol
(2014) - et al.
Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors
Immunity
(1995) - et al.
Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms
Blood
(2014) - et al.
Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis
Cell
(1998) - et al.
Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule
J Biol Chem
(2015) - et al.
Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid
Blood
(1981) - et al.
In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins
Blood
(1996)
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial
Lancet Oncol
Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies
Haematologica
Natural course and biology of CML
Ann Hematol
Cancer. Addiction to oncogenes–the Achilles heal of cancer
Science
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
N Engl J Med
Chromosome studies on normal and leukemic human leukocytes
J Natl Cancer Inst
Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining
Nature
Structural organization of the bcr gene and its role in the Ph' translocation
Nature
In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome
Proc Natl Acad Sci U S A
The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity
J Exp Med
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Nat Med
Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis
Clin Cancer Res
Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis
Proc Natl Acad Sci U S A
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies
Cancer Res
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
N Engl J Med
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
N Engl J Med
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
N Engl J Med
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
N Engl J Med
Ruxolitinib versus standard therapy for the treatment of polycythemia vera
N Engl J Med
Cited by (3)
Unique somatic variants in DNA from urine exosomes of individuals with bladder cancer
2021, Molecular Therapy Methods and Clinical DevelopmentCitation Excerpt :Thus, the prevalence of variants in the 3′ UTRs in this particular cohort likely reflects a true pattern and requires further investigation in multiple extended cohorts of affected individuals. The most affected cancer-driving nodes found in urine exoDNA and tumor tissue DNA across the majority of the individuals included AKT1-3, BCR, FOXO3, IGF2, KRAS, and MTOR/RPTOR, all of which affect cancer cell proliferation, survival, and metabolism.71–79 Frequent mutations in the SMO/WNT/FZD module found in 3 of 6 patients suggest that a fraction of cells underwent epithelial-to-mesenchymal transition80 or potentially activated the tumor stroma.81,82
Blocking DNA Damage Repair May Be Involved in Stattic (STAT3 Inhibitor)-Induced FLT3-ITD AML Cell Apoptosis
2021, Frontiers in Cell and Developmental BiologyEmerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas
2018, Expert Opinion on Therapeutic Targets
Disclosure Statement: Nothing to disclose.